Translate page

English English
en Englishbg Bulgarianzh-CN Chinese (Simplified)hr Croatiancs Czechda Danishnl Dutchfi Finnishfr Frenchde Germanel Greekiw Hebrewhi Hindiid Indonesianit Italianja Japaneseko Koreanmk Macedonianpl Polishpt Portuguesero Romanianru Russiansr Serbiansk Slovaksl Slovenianes Spanishsv Swedishth Thaitr Turkishvi Vietnamese

Virtual Education

VEP 2017: How to treat CML in 2017?

We are pleased to make available a new series of presentations on various aspects of CML management that were first presented at the 22nd Meeting of the European Hematology Association (EHA) in Madrid in 2017. Modules currently featured include; how to treat CML in 2017, factors affecting clinical decision making in relapsed and refractory CP-CML patients and treatment outcomes of bosutinib from real-world data. 

 We are very grateful for the support of Brandcast media to produce these webstreams.
EHA Andreas Hochhaus

 

 

  

         

 

How to treat CML in 2017?
Andreas Hochhaus, Universitätsklinikum Jena, Germany 

  • Objectives of treatment optimization
  • Choice of initial therapy
  • Clinical data on 1st and 2nd generation TKI's
  • Comorbidities in CML at diagnosis
  • Main adverse events of TKI's
  • ELN recommendations for monitoring of first-line TKI therapy
  • Recommendations for switch: CP-CML
  • Management of blast crisis
  • Limitations of TKI therapies
  • Discussion: are we ready for routine stopping procedure?
  • Recommendations on CML management 2013 - 2017

This presentation is adapted from the one presented during the CML educational session at EHA. It lasts around 30 minutes.